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Abstract
A new synthesis of deoxynojirimycin (DNJ) analogues (galacto- and altrose configuration) has been
achieved through a functionalized cyclopentene derivative crafted from the norbornyl system, employing
double reductive amination as the key step. The new DNJ analogues have been evaluated against various
glycosidases and found to be moderate to strong inhibitors.
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Natural and unnatural polyhydroxylated piperidines have aroused the widespread attention of
organic chemists in recent years due to their very promising biological activity profile and syn-
thetically challenging structural features present in them.1 These polyhydroxylated piperidines
generically termed as iminosugars (‘azasugars’), closely resemble monosaccharides in terms of
their shape and structure; they competitively inhibit glycosidases, enzymes responsible for the
cleavage of glycosidic bonds. In azasugars, the ring oxygen is replaced by nitrogen, which can be
protonated under physiological pH, thus mimicking the glycopyranosyl cation. Inhibition of
glycosidases is projected to be useful in the treatment of carbohydrate related metabolic disorders
and holds promise for the development of drugs for the treatment of cancer, diabetes, HIV and
viral infections.2 A large number of naturally occurring azasugars and their synthetically designed
analogues are known, and nojirimycin 1, 1-deoxynojirimycin 21a (DNJ), amidine 33a and deoxy-
fuconojirimycin 43b are typical examples, all of which have been found to inhibit carbohydrate
processing enzymes.
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A wide range of synthetic strategies have been devised to access polyhydroxylated piper-
idines.1,3,4 Prominent among these, which are also of general applicability, are the restructuring
or elaboration of chiral pool derived precursors (carbohydrates, amino acids, myo-inositol, tar-
taric acid etc.),1a,3,4 chemoenzymatic4b,c and microbial (hydroxylated aromatics) approaches,4d
Diels–Alder4e and hetero-Diels–Alder4f cycloaddition based routes, and aza-Achmatowicz reaction
(furan reorganization).4g,h Herein, we report a new synthesis of deoxynojirimycin analogues ori-
ginating from a bicyclo[2.2.1]heptane (norbornyl) system.
Recently we have developed a fragmentation reaction-based strategy to extract a highly func-
tionalized and stereochemically well defined cyclopentene derivative 8 from the readily available
norbornyl derivative 5 through the intermediacy of 6 and 7, respectively, Scheme 1.5 Cyclo-
pentane derivative 8 has now been further restructured to DNJ analogues6 employing double
reductive amination as the key step.
The free hydroxyl group in the iodocyclopentane 8 was transformed to a leaving group through
mesylation to furnish the mesylate 9. Acetolysis of 9 led to elimination followed by allylic dis-
placement to furnish acetoxycyclopentene 10, in which the olefinic moiety was well positioned for
further manipulation. OsO4-mediated catalytic dihydroxylation of 10 proceeded in a stereo-
selective manner to give 117 and 127 (10:90), Scheme 2. While diastereomers 11 and 12 were
separated and characterized, it was not considered necessary for the next step. Sodium periodate-
induced glycol cleavage in 11 and 12 furnished the labile keto-aldehyde 13 which was as such
subjected to double-reductive amination in the NaCNBH3–BnNH2 milieu to furnish 14 as a
Scheme 1.
Scheme 2. Reagents and conditions: (a) NaOAc, DMF, 105C, 6 h, 77%; (b) OsO4, NMMO (50% aq. sol.), Me2CO:
H2O (4:1), 48 h, 86%; (c) NaIO4 (1.3 equiv.), DCM, 0
C; (d) BnNH2, AcOH, NaCNBH3, 20 h, ^10C!rt, 30% for
two steps; (e) KOH, MeOH, 2 h, 90%
mixture of two diastereomers (1:2). Base mediated hydrolysis of the acetate group in 14 and
chromatographic separation of the diastereomers led to 157 and 16,7 which were fully character-
ized as having the altrose and galactose stereochemical disposition,6 respectively, on the basis of
incisive NMR (COSY, NOE) studies (Scheme 2).
In independent deprotection sequences, 15 and 16 were transformed to the hydrochlorides of
N-benzyl DNJ derivatives 17 and 19, respectively, Scheme 3. In a similar manner, hydrochlorides
of altro-deoxynojirimycin methyl ether 186 and galactostatin methyl ether 20 were obtained from
15 and 16, respectively, and duly characterized.7
Scheme 3. Reagents and conditions: (a) 2.5% HCl: Et2O (1:1), 18 h, >90%; (b) H2, Pd/C (10%), EtOH, 18 h, 60%;
2.5% HCl: Et2O (1:1), 95%; (c) same as (a), 90%; (d) same as (b), quantitative
Table 1
Inhibition constantsa,b (Ki) in mm
Compounds 17–20 were assayed for their glycosidase inhibition activity (Table 1). All mea-
surements were carried out with the corresponding nitrophenyl glycoside substrates in aqueous
buer at appropriate pH. Galactostatin methyl ether 20 was found to be a selective and potent
inhibitor of a-galactosidase and there was no inhibition observed for a- and b-glucosidases and
b-galactosidase. It was notable that inhibitory activity of 20 was approximately 1000 fold less
than of the natural product galactostatin 21.6 When 20 was compared with its benzyl derivative
19, a marked decline in inhibitory activity as well as selectivity was observed and the latter was
only a moderate inhibitor of a-galactosidase, and a weak inhibitor of a-glucosidase. Interestingly,
18 (C2-epimer of 20) was also found to be a selective inhibitor of a-galactosidase whereas its
benzyl derivative was found to be essentially ineective towards glycosidase inhibition.
In short, we have devised a new synthesis of DNJ derivatives 17–20 from the cyclopentanoid
building block 7. Our results of enzymatic assays reveal that N- and O-substituents have sig-
nificant consequence on the glycosidase activity and selectivity.
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Selected spectral data (1H NMR and 13C NMR) 15 H (300 MHz, CDCl3): 7.32–7.28 (5H, m, Ar-H), 4.18 (1H, dd,
J=2.7, 6.0 Hz), 4.08 (1H, dd, J=4.8, 6.0 Hz), 4.03 (1H, 12ABq, J=13.2 Hz), 3.78 (1H,
1
2ABq, J=13.2 Hz), 3.66
(1H, dd, J=4.2, 10 Hz), 3.54–3.45 (3H, series of m), 3.35 (3H, s), 3.15–3.10 (1H, m), 2.76 (1H, dd, J=3.3, 13.5
Hz), 2.62 (1H, dd, J=7.8, 13.5 Hz), 1.56 (3H, s), 1.36 (3H, s); C (75 MHz, CDCl3): 138.72, 128.88 (2C), 128.51
(2C), 127.42, 108.1, 76.43, 75.51, 75.01, 60.76, 60.46, 59.37, 57.20, 45.26, 28.06, 25.51. 16 H (300 MHz, CDCl3):
7.34–7.26 (5H, m, Ar-H), 4.31 (1H, dd, J=2.2, 6.0 Hz), 4.14 (1H, dd as t, J=6.0 Hz), 4.12–4.10 (2H, m), 3.99–3.89
(2H, series of m), 3.50–3.42 (1H, m), 3.42–3.38 (1H, m), 3.40 (3H, s), 3.0 (1H, dd, J=4.5, 11.7 Hz), 2.68 (1H, m),
1.91 (1H, dd, J=10.8, 11.7 Hz), 1.57 (3H, s), 1.38 (3H, s); C (75 MHz, CDCl3): 137.73 (C), 129.14 (CH, 2C),
128.35 (CH, 2C), 127.24 (C), 109.45 (C), 79.38 (CH), 78.96 (CH), 77.63 (CH), 61.71 (CH2), 60.63 (CH), 57.86
(CH3), 56.69 (CH2) 51.69 (CH2), 28.28 (CH3), 26.26 (CH3). 17 H (300 MHz, D2O): 7.41 (5H, br. s), 4.26-3.98 (6H,
series of m), 3.55 (1H, br. s), 3.4-3.08 (3H, series of m), 3.16 (3H, s); C (100 MHz, D2O): 132.84 (2C), 131.55,
130.57 (2C), 129.36, 76.23, 67.43, 65.96, 64.62, 63.68, 58.31, 55.81, 49.07. 18 H (300 MHz, D2O): 4.0 (1H, dd as t,
J=3.6 Hz), 3.82 (1H, dt, J=3.6, 12.3 Hz), 3.70–3.65 (3H, series of m), 3.38–3.34 (1H, m), 3.29 (3H, s), 3.25–3.12
(2H, series of m); C (100 MHz, D2O): 76.22 (CH), 67.40 (CH), 64.49 (CH), 59.00 (CH2), 57.67 (CH3), 56.37 (CH),
41.36 (CH2). 19 H (300 MHz, D2O): 7.51 (5H, br. s), 4.26 (2H, m), 4.19–4.17 (3H, m), 3.68–3.60 (2H, m), 3.54
(1H, br. s), 3.43 (1H, dd, J=4.5, 12.3 Hz), 3.30 (3H, s), 2.76 (1H, dd, J=10.5, 12 Hz), C (100 MHz, D2O): 132.85
(2C), 131.64, 130.57 (2C), 129.45, 74.91, 72.75, 70.78, 65.92, 59.68, 59.44, 58.27, 50.63. 20: H (300 MHz, D2O):
4.02–3.99 (m, 1H), 3.75–3.50 (5H, series of m), 3.34 (3H, s), 3.27–3.23 (1H, m), 2.70–2.62 (1H, t like m); C (100
MHz, D2O): 74.93 (CH), 72.56 (CH), 67.40 (CH), 60.53 (CH), 59.60 (CH2), 58.85 (CH3), 44.24 (CH2).
